

What is claimed is:

1. A method for the prevention of thrombotic episodes in a postoperative human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily, beginning approximately two hours prior to abdominal surgery.

2. A method as recited in claim 1, wherein said administration is continued for approximately 7-10 days.

3. A method for the treatment of thrombotic episodes in a postoperative human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily, beginning approximately two hours prior to abdominal surgery.

4. A method as recited in claim 3, wherein said administration is continued for approximately 7-10 days.

5. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily, beginning approximately two hours prior to abdominal surgery.

6. A method as recited in claim 5, wherein said administration is continued for approximately 7-10 days.

7. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a postoperative human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily, beginning approximately two hours prior to abdominal surgery.

8. A method as recited in claim 7, wherein said administration is continued for approximately 7-10 days.

9. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient 30mg enoxaparin sodium by subcutaneous injection once daily, beginning approximately 12 to 24 hours after hip or knee replacement surgery.

10. A method as recited in claim 9, wherein said administration is continued for approximately 7-10 days.

11. A method for the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin

sodium by subcutaneous injection once daily, beginning approximately 12 to 24 hours after hip or knee replacement surgery.

12. A method as recited in claim 11, wherein said administration is continued for approximately 7-10 days.

13. A method for the prevention of venous thrombosis in a human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily, beginning approximately 12 to 24 hours after hip or knee replacement surgery.

14. A method as recited in claim 13, wherein said administration is continued for approximately 7-10 days.

15. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a postoperative human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily, beginning approximately 12 to 24 hours after hip or knee replacement surgery.

16. A method as recited in claim 15, wherein said administration is continued for approximately 7-10 days.

17. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily, beginning 12 hours before hip replacement surgery.

18. A method as recited in claim 17, wherein said administration is continued for approximately three weeks.

19. A method for the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily, beginning 12 hours before hip replacement surgery.

20. A method as recited in claim 19, wherein said administration is continued for approximately three weeks.

21. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily, beginning 12 hours before hip replacement surgery.

22. A method as recited in claim 21, wherein said administration is continued for approximately three weeks.

23. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily, beginning 12 hours before hip replacement surgery.

24. A method as recited in claim 23, wherein said administration is continued for approximately three weeks.

25. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment during acute illness, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily.

26. A method as recited in claim 25, wherein said administration is continued for approximately 6 to 11 days.

27. A method for the treatment of thrombotic episodes in a human patient with severe renal impairment during acute illness, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily.

28. A method as recited in claim 27, wherein said administration is continued for approximately 6 to 11 days.

29. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment during acute illness, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily.

30. A method as recited in claim 29, wherein said administration is continued for approximately 6 to 11 days.

31. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a human patient with severe renal impairment during acute illness, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily.

32. A method as recited in claim 31, wherein said administration is continued for approximately 6 to 11 days.

33. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily.

34. A method for the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily.

35. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily.

36. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a patient with severe renal impairment, comprising administering to said patient 30mg of enoxaparin sodium by subcutaneous injection once daily.

37. An article of manufacture for use in connection with the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising enoxaparin sodium contained within a syringe and instructions for the use of said enoxaparin sodium, said instructions being designed to achieve administration to said patient of 30 mg of said enoxaparin sodium by subcutaneous injection once daily.

38. An article of manufacture for use in connection with the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising enoxaparin sodium contained within a syringe and instructions for the use of said enoxaparin sodium, said instructions being designed to achieve administration to said patient of 30 mg of said enoxaparin sodium by subcutaneous injection once daily.

39. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily.

40. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily.

41. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily.

42. A method for the treatment of thrombotic episodes in a human with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily.

43. A method for the treatment of thrombotic episodes in a human with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily.

44. A method for the treatment of thrombotic episodes in a human with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily.



45. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily.

46. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient between 25mg and 35mg of enoxaparin sodium once daily.

47. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily.

48. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily.

49. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily.

50. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily.

51. A method for the prevention of thrombotic episodes in a postoperative human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

52. A method for the prevention of thrombotic episodes in a postoperative human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

53. A method for the prevention of thrombotic episodes in a postoperative human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

54. A method for the treatment of thrombotic episodes in a postoperative human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

55. A method for the treatment of thrombotic episodes in a postoperative human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

56. A method for the treatment of thrombotic episodes in a postoperative human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

57. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

58. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

59. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

60. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a postoperative human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

61. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a postoperative human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

62. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a postoperative human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning prior to abdominal surgery.

63. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

64. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

65. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

66. A method for the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

67. A method for the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

68. A method for the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

69. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient

from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

70. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

71. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

72. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

73. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

74. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning after hip or knee replacement surgery.

75. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning before hip replacement surgery.

76. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning before hip replacement surgery.

77. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning before hip replacement surgery.

78. A method for the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning before hip replacement surgery.

79. A method for the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning before hip replacement surgery.

80. A method for the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning before hip replacement surgery.

81. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning before hip replacement surgery.

82. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning before hip replacement surgery.

83. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning before hip replacement surgery.



84. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a human patient with severe renal impairment, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily beginning before hip replacement surgery.

85. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a human patient with severe renal impairment, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily beginning before hip replacement surgery.

86. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a human patient with severe renal impairment, comprising administering to said patient about 30mg of enoxaparin sodium once daily beginning before hip replacement surgery.

87. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment during acute illness, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily.

88. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment during acute illness, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily.

89. A method for the prevention of thrombotic episodes in a human patient with severe renal impairment during acute illness, comprising administering to said patient about 30mg of enoxaparin sodium once daily.

90. A method for the treatment of thrombotic episodes in a human with severe renal impairment during acute illness, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily.

91. A method for the treatment of thrombotic episodes in a human with severe renal impairment during acute illness, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily.

92. A method for the treatment of thrombotic episodes in a human with severe renal impairment during acute illness, comprising administering to said patient about 30mg of enoxaparin sodium once daily.

93. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment during acute illness, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily.

94. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment during acute illness, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily.

95. A method for the prevention of venous thrombosis in a postoperative human patient with severe renal impairment during acute illness, comprising administering to said patient about 30mg of enoxaparin sodium once daily.

96. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a patient with severe renal impairment during acute illness, comprising administering to said patient from more than 20mg to less than 40mg of enoxaparin sodium once daily.

97. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a patient with severe renal impairment during acute illness, comprising administering to said patient from 25mg to 35mg of enoxaparin sodium once daily.

98. A therapeutic method for controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a patient with severe renal impairment during acute illness, comprising administering to said patient about 30mg of enoxaparin sodium once daily.

99. An article of manufacture for use in connection with the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising enoxaparin sodium and instructions for the use of said enoxaparin sodium, said instructions being designed to achieve administration to said patient of from more than 20mg to less than 40mg of enoxaparin sodium once daily.

100. An article of manufacture as recited in claim 99, wherein said enoxaparin sodium is contained within a syringe.

101. An article of manufacture as recited in claim 99, wherein said enoxaparin sodium is contained within a vial.

102. An article of manufacture as recited in claim 99, wherein said administration is by subcutaneous injection.

103. An article of manufacture for use in connection with the prevention of thrombotic episodes in a human patient with severe renal impairment, comprising enoxaparin sodium and instructions for the use of said enoxaparin sodium, said instructions being designed to achieve administration to said patient of 30mg of enoxaparin sodium once daily, wherein said enoxaparin sodium and said instructions are contained within a package.

104. An article of manufacture for use in connection with the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising enoxaparin sodium and instructions for the use thereof, said instructions being designed to achieve administration to said patient of from more than 20mg to less than 40mg of enoxaparin sodium once daily.

105. An article of manufacture as recited in claim 104, wherein said enoxaparin sodium is contained within a syringe.

106. An article of manufacture as recited in claim 104, wherein said enoxaparin sodium is contained within a vial.

107. An article of manufacture as recited in claim 104, wherein said administration is by subcutaneous injection.

108. An article of manufacture for use in connection with the treatment of thrombotic episodes in a human patient with severe renal impairment, comprising enoxaparin sodium and instructions for the use of said enoxaparin sodium, said instructions being designed to achieve administration to said patient of 30mg of enoxaparin sodium once daily, wherein said enoxaparin sodium and said instructions are contained within a package.

109. An article of manufacture for use in connection with the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising enoxaparin sodium contained within a syringe and instructions for the use of said enoxaparin sodium, said instructions being designed to achieve administration to said patient of 30 mg of said enoxaparin sodium by subcutaneous injection once daily.

110. An article of manufacture for use in connection with the prevention of venous thrombosis in a postoperative human patient with severe renal impairment, comprising enoxaparin sodium and instructions for the use of said enoxaparin sodium, said instructions being designed to achieve administration to said patient of from more than 20mg to less than 40mg of enoxaparin sodium once daily.

111. An article of manufacture as recited in claim 110, wherein said enoxaparin sodium is contained within a syringe.

112. An article of manufacture as recited in claim 110, wherein said enoxaparin sodium is contained within a vial.

113. An article of manufacture as recited in claim 110, wherein said administration is by subcutaneous injection.

114. An article of manufacture for use in connection with the prevention of venous thrombosis in a postoperative human patient with severe renal impairment,

comprising enoxaparin sodium and instructions for the use of said enoxaparin sodium, said instructions being designed to achieve administration to said patient of 30mg of enoxaparin sodium once daily, wherein said enoxaparin sodium and said instructions are contained within a package.

115. An article of manufacture for use in connection with controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a human patient with severe renal impairment, comprising enoxaparin sodium contained within a syringe and instructions for the use of said enoxaparin sodium, said instructions being designed to achieve administration to said patient of 30 mg of said enoxaparin sodium by subcutaneous injection once daily.

116. An article of manufacture for use in connection with controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a human patient with severe renal impairment, comprising enoxaparin sodium and instructions for the use of said enoxaparin sodium, said instructions being designed to achieve administration to said patient of from more than 20mg to less than 40mg of enoxaparin sodium once daily.

117. An article of manufacture as recited in claim 116, wherein said enoxaparin sodium is contained within a syringe.

118. An article of manufacture as recited in claim 116, wherein said enoxaparin sodium is contained within a vial.

119. An article of manufacture as recited in claim 116, wherein said administration is by subcutaneous injection.

120. An article of manufacture for use in connection with controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks in a human patient with severe renal impairment, comprising enoxaparin sodium and instructions for the use of said enoxaparin sodium, said instructions being designed to achieve administration to said patient of 30mg of enoxaparin sodium once daily, wherein said enoxaparin sodium and said instructions are contained within a package.